The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling

Vencken, Peggy M. L. H.; Kriege, Mieke; Hooning, Maartje; Menke‐Pluymers, Marian B.; Heemskerk‐Gerritsen, Bernadette A. M.; van Doorn, Lena C.; Collée, Margriet M.; Jager, Agnes; van Montfort, Cees; Burger, Curt W.; Seynaeve, Caroline

doi:10.1002/cncr.27839

Cited by 40BRCA gene mutations in cancerMultiple and Secondary Primary CancersCancer Risks and Factors

The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling

Open access

Vencken, Peggy M. L. H., Kriege, Mieke, Hooning, Maartje, Menke‐Pluymers, Marian B., Heemskerk‐Gerritsen, Bernadette A. M., van Doorn, Lena C., Collée, Margriet M., Jager, Agnes +3 more·2013·Cancer

DOI 10.1002/cncr.27839

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The objective of this study was to assess the incidence of primary breast cancer (PBC) and contralateral breast cancer (CBC) in patients who had BRCA1/BRCA2‐associated epithelial ovarian cancer (OC). METHODS: From the database of the Rotterdam Family Cancer Clinic, patients who had BRCA‐associated OC without a history of unilateral breast cancer (BC) (at risk of PBC; n = 79) or with a history of unilateral BC (at risk of CBC; n = 37) were selected. The control groups consisted of unaffected BRCA mutation carriers (n = 351) or mutation carriers who had a previous unilateral BC (n = 294), respectively. The risks of PBC and CBC were calculated using the Kaplan‐Meier survival method with death considered as a competing risk event. RESULTS: Women with BRCA‐associated OC had lower 2‐year, 5‐year, and 10‐year risks of PBC (3%, 6%, and 11%, respectively) compared with unaffected mutation carriers (6%, 16%, and 28%, respectively; P = .03), although they had a considerably higher mortality rate at similar time points (13%, 33%, and 61%, respectively, vs 1%, 2%, and 2%, respectively; P < .001). In BRCA mutation carriers with a previous unilateral BC, the 2‐year, 5‐year, and 10‐year risks of CBC were nonsignificantly lower in patients with OC than in those without OC (0%, 7%, and 7%, respectively, vs 6%, 16%, and 34%, respectively; P = .06), whereas the mortality rate was higher in patients with OC (19%, 34%, and 55%, respectively, vs 4%, 11%, and 21%, respectively; P < .001). CONCLUSIONS: Patients with BRCA‐associated OC had a lower risk of developing a subsequent PBC or CBC than mutation carriers without OC, whereas the risk of dying from OC was greater than the risk of developing BC. These data may facilitate more tailored counseling for this patient subgroup, although confirmative studies are warranted. Cancer 2013. © 2012 American Cancer Society.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cncr.27839

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Four studies including selected patients and accounting for competing risks reported higher 10-year contralateral breast cancer risk estimates (21%-27%), similar to the risk observed in this study for mutation carriers with a family history of breast cancer (25%).
“Four studies including”
From Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers (2016) · cites this paper as [34]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680 · see citing works
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
Ford, D., Easton, D., Stratton, M. R., Narod, S., Goldgar, D., Devilee, P., Bishop, D., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · American Journal of Human Genetics · doi:10.1086/301749 · Cited by 2,766 · see citing works
Meta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802 · see citing works
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
Kriege, M., Brekelmans, C. T. M., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Peterse, H. L., Tilanus‐Linthorst, M. M. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031759 · Cited by 1,686 · see citing works
Self-citation
Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality
Domchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494 · see citing works
Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171 · see citing works
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szállási, Z., Li, Q., Birkbak, N. J., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 982 · see citing works
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with aBRCA1orBRCA2Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973 · see citing works
Self-citation
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn442 · Cited by 939 · see citing works
A note on competing risks in survival data analysis
Satagopan, J. M., Ben‐Porat, L., Berwick, M., Robson, M. E., Kutler, D. I., & Auerbach, A. D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602102 · Cited by 752 · see citing works
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A. F., Snyder, C., Watson, P. A., Cannon‐Albright, L., Isaacs, C. J., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 670 · see citing works
Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study
Kauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., Isaacs, C. J., Evans, D. G., Lynch, H. T., Eeles, R. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9626 · Cited by 586 · see citing works
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan, D. S., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., Ardern-jones, A., Norman, A., Kaye, S., & Gore, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1703 · Cited by 489 · see citing works
Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study
Eisen, A. F., Lubiński, J., Klijn, J. G. M., Møller, P., Lynch, H. T., Offit, K., Weber, B., Rebbeck, T., Neuhausen, S. L., Ghadirian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7138 · Cited by 442 · see citing works
Prophylactic mastectomy for the prevention of breast cancer
Lostumbo, L., Carbine, N. E., & Wallace, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub3 · Cited by 402 · see citing works
Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in BRCA1/2-Associated Stage I/II Breast Cancer
Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., Harris, E. E., Gaffney, D. K., Haffty, B. G., Dawson, L. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7888 · Cited by 340 · see citing works
Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Graeser, M. K., Engel, C., Rhiem, K., Gadzicki, D., Bick, U., Kast, K., Froster, U. G., Schlehe, B., Bechtold, A., Arnold, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9430 · Cited by 314 · see citing works
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.
Schwartz, M. D., Lerman, C., Brogan, B. M., Peshkin, B., Halbert, C., Demarco, T. A., Lawrence, W., Main, D., Finch, C., Magnant, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.086 · Cited by 248 · see citing works
Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers
Kurian, A. W., Sigal, B. M., & Plevritis, S. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7991 · Cited by 243 · see citing works
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases
Brekelmans, C. T. M., Tilanus-Linthorst, M. M. A., Seynaeve, C., vd Ouweland, A., Menke-Pluymers, M. B. E., Bartels, C. C. M., Kriege, M., van Geel, A. N., Burger, C. W., Eggermont, A. M. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.009 · Cited by 233 · see citing works
Self-citation
Preventive therapy for breast cancer: a consensus statement
Cuzick, J. M., DeCensi, A., Arun, B. K., Brown, P. H., Castiglione, M. M., Dunn, B., Forbes, J., Glaus, A., Howell, A., von Minckwitz, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70030-4 · Cited by 220 · see citing works
First experiences in screening women at high risk for breast cancer with MR imaging
Tilanus‐Linthorst, M. M. A., Obdeijn, I.-M., Bartels, K. C. M., de Koning, H. J., & Oudkerk, M. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006480106487 · Cited by 216 · see citing works
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
Vencken, P. M. L. H., Kriege, M., Hoogwerf, D., Beugelink, S., van der Burg, M. E. L., Hooning, M. J., Berns, E., Jager, A., Collee, M. J., Burger, C. W., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq628 · Cited by 212 · see citing works
Self-citation
Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe, K., Lubiński, J., Ghadirian, P., Lynch, H., Kim-sing, C., Friedman, E., Foulkes, W., Domchek, S., Ainsworth, P., Isaacs, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6078 · Cited by 197 · see citing works
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age
van der Kolk, D. M., de Bock, G. H., Leegte, B. K., Schaapveld, M., Mourits, M. J. E., de Vries, J., van der Hout, A. H., & Oosterwijk, J. C. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0805-3 · Cited by 187 · see citing works
BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study
Rijnsburger, A. J., Obdeijn, I.-M., Kaas, R., Tilanus‐Linthorst, M. M. A., Boetes, C., Loo, C. E., Wasser, M. N. J. M., Bergers, E., Kok, T., Muller, S. H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2294 · Cited by 183 · see citing works
Self-citation
Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction
Antoniou, A. C., Beesley, J., McGuffog, L., Sinilnikova, O. M., Healey, S. C., Neuhausen, S. L., Ding, Y. C., Rebbeck, T. R., Weitzel, J. N., Lynch, H. T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1907 · Cited by 179 · see citing works
Self-citation
BRCA mutations in the management of breast cancer: the state of the art
Narod, S. A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.166 · Cited by 160 · see citing works
Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells
Tyagi, A., Agarwal, C., Chan, D. C. F., & Agarwal, R. (2004) · Oncology Reports · doi:10.3892/or.11.2.493 · Cited by 158 · see citing works
The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers
Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Foulkes, W. D., Warner, E., Olopade, O. I., Eisen, A. F., Weber, B., et al. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.09.039 · Cited by 157 · see citing works
Bilateral prophylactic mastectomy in women with inherited risk of breast cancer – Prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery
Gahm, J., Wickman, M., & Brandberg, Y. (2010) · The Breast · doi:10.1016/j.breast.2010.05.003 · Cited by 143 · see citing works
Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
Verhoog, L., Brekelmans, C., Seynaeve, C., Meijers-Heijboer, E., & Klijn, J. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1239 · Cited by 135 · see citing works
Self-citation
Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up of BRCA1 Mutation Carriers
Kramer, J. L., Velazquez, I. A., Chen, B. E., Rosenberg, P. S., Struewing, J. P., & Greene, M. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9199 · Cited by 135 · see citing works
3–14 The Risk of Ovarian Cancer After Breast Cancer in BRCA1 and BRCA2 Carriers
Lu, K. H. (2005) · Breast Diseases A Year Book Quarterly · doi:10.1016/s1043-321x(05)80198-5 · Cited by 115 · see citing works
Pharmacological and small interference RNA‐mediated inhibition of breast cancer‐associated fatty acid synthase (oncogenic antigen‐519) synergistically enhances Taxol (paclitaxel)‐induced cytotoxicity
Menéndez, J. A., Vellón, L., Colomer, R., & Lupu, R. (2005) · International Journal of Cancer · doi:10.1002/ijc.20754 · Cited by 110 · see citing works
Uptake, Time Course, and Predictors of Risk-Reducing Surgeries in BRCA Carriers
Beattie, M. S., Crawford, B., Lin, F., Vittinghoff, E., & Ziegler, J. L. (2009) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2008.0067 · Cited by 96 · see citing works
BRCA1 and implications for response to chemotherapy in ovarian cancer
Quinn, J. E., Carser, J., James, C. R., Kennedy, R. D., & Harkin, D. P. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.12.015 · Cited by 76 · see citing works
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer
The WECARE Collaborative Study Group, Reding, K. W., Bernstein, J. L., Langholz, B. M., Bernstein, L., Haile, R. W., Begg, C. B., Lynch, C. F., CONCANNON, P. J., Borg, Å., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0769-3 · Cited by 62 · see citing works
Mammography benefit in the Canadian National Breast Screening Study‐2: A model evaluation
Rijnsburger, A. J., van Oortmarssen, G. J., Boer, R., Draisma, G., To, T. M., Miller, A. B., & de Koning, H. J. (2004) · International Journal of Cancer · doi:10.1002/ijc.20143 · Cited by 52 · see citing works
Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer
Kriege, M., Brekelmans, C. T. M., Peterse, H. L., Obdeijn, I. M., Boetes, C., Zonderland, H. M., Muller, S. H., Kok, T., Manoliu, R. A., Besnard, A. P. E., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9341-6 · Cited by 45 · see citing works
Self-citation
Therapeutic Approaches for Women Predisposed to Breast Cancer
Nathanson, K. L., & Domchek, S. M. (2010) · Annual Review of Medicine · doi:10.1146/annurev-med-010910-110221 · Cited by 35 · see citing works
Prophylactic Mastectomy in High Risk Patients: A Practice-Based Review of the Indications. Do We Follow Guidelines?
Hoover, D. J., Paragi, P. R., Santoro, E., Schafer, S., & Chamberlain, R. S. (2010) · Breast Disease · doi:10.3233/bd-2009-0291 · Cited by 13 · see citing works
Management Options after Prophylactic Surgeries in Women with BRCA Mutations: A Review
Allain, D. C., Sweet, K. M., & Agnese, D. M. (2007) · Cancer Control · doi:10.1177/107327480701400403 · Cited by 10 · see citing works

Flagged first, then by citations

Research works printed but not linked: 3

Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 pene- trance. J Clin Oncol. 2007;25:1329-1333.
Domchek SM, Friebel TM, Singer CF, et al. Association of risk- reducing surgery in BRCA1 or BRCA2 mutation carriers with can- cer risk and mortality. JAMA. 2010;304:967-975.
Kauff ND, Domcheck SM, Friebel TM, et al. RRSO for the pre- vention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331-1337.

Sorted by citations

A survey of current trends in computational drug repositioning
Li, J., Zheng, S., Chen, B., Butte, A. J., Swamidass, S. J., & Lu, Z. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv020 · Cited by 555 · see citing works
Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers
van den Broek, A. J., van ’t Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J., Smit, V. T. H. B. M., Cornelisse, C. J., van Beek, M., Janssen-Heijnen, M. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3942 · Cited by 104 · see citing works
Self-citation
Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis.
Molina-Montes, E., Pérez-Nevot, B., Pollán, M., Sánchez-Cantalejo, E., Espín, J., & Sánchez, M. (2014) · Breast · doi:10.1016/j.breast.2014.10.005 · Cited by 86 · see citing works
Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee, J., Giannakeas, V., Karlan, B. Y., Lubiński, J., Gronwald, J., Rosen, B. P., McLaughlin, J. R., Risch, H. A., Sun, P., Foulkes, W. D., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.02.032 · Cited by 41 · see citing works
The novel pillar[5]arene derivative for recyclable electrochemical sensing platform of homogeneous DNA hybridization
Yang, S., Liu, L., You, M., Zhang, F., Liao, X., & He, P. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2015.12.090 · Cited by 40 · see citing works
Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis
Page, C. L., Rahimi, K., Rodrigues, M. J., Heinzelmann-Schwarz, V. A., Recio, N., Tommasi, S., Bataillon, G., Portelance, L., Golmard, L., Meunier, L., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.019 · Cited by 27 · see citing works
Genetic testing and familial implications in breast-ovarian cancer families
Oosterwijk, J. C., de Vries, J., Mourits, M. J. E., & de Bock, G. H. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.05.002 · Cited by 28 · see citing works
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients
Su, L., Xu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2020) · International Journal of Cancer · doi:10.1002/ijc.32918 · Cited by 21 · see citing works
Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer
Gamble, C. R., Havrilesky, L. J., Myers, E. R., Chino, J., Hollenbeck, S. T., Plichta, J. K., Marcom, P. K., Hwang, E. S., Kauff, N. D., & Greenup, R. A. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-5995-z · Cited by 19 · see citing works
Genetic predisposition in gynecologic cancers
Daniels, M. S., & Lu, K. H. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.08.005 · Cited by 19 · see citing works
Managing hereditary breast cancer risk in women with and without ovarian cancer
Peters, M. L. B., Garber, J. E., & Tung, N. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.04.013 · Cited by 18 · see citing works
Does perceived risk predict breast cancer screening use? Findings from a prospective cohort study of female relatives from the Ontario site of the Breast Cancer Family Registry
Walker, M. J., Mirea, L., Glendon, G., Ritvo, P., Andrulis, I. L., Knight, J. A., & Chiarelli, A. M. (2014) · The Breast · doi:10.1016/j.breast.2014.04.001 · Cited by 17 · see citing works
Clinical characteristics and survival outcomes of patients with both primary breast cancer and primary ovarian cancer
Chen, C., Xu, Y., Huang, X., Mao, F., Shen, S., Xu, Y., & Sun, Q. (2020) · Medicine · doi:10.1097/md.0000000000021560 · Cited by 11 · see citing works
Survival Outcomes of Patients with Primary Breast Cancer Following Primary Ovarian Cancer
Zhang, W., Zhang, W., Lin, Z., Wang, F., Li, M., Zhu, L., Yu, Y., & Gao, Y. (2019) · Medical Science Monitor · doi:10.12659/msm.914163 · Cited by 9 · see citing works
Breast cancer surveillance following ovarian cancer in BRCA mutation carriers
John, C. S., Fong, A., Alban, R. F., Gillen, J. M., Moore, K. M., Walsh, C., Li, A. J., Rimel, B. J., Amersi, F. F., & Cass, I. A. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.10.077 · Cited by 9 · see citing works
Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers
Fong, A., Cass, I. A., John, C. S., Gillen, J. M., Moore, K. M., Gangi, A., Walsh, C., Li, A. J., Rimel, B. J., Karlan, B. Y., et al. (2020) · The American Surgeon · doi:10.1177/0003134820964208 · Cited by 8 · see citing works
Counselling Framework for Germline BRCA1/2 and PALB2 Carriers Considering Risk-Reducing Mastectomy
Wong, S. M., Apostolova, C., Eisenberg, E., & Foulkes, W. D. (2024) · Current Oncology · doi:10.3390/curroncol31010023 · Cited by 8 · see citing works
Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy
Evans, D. G., Morgan, R. D., Crosbie, E. J., Howell, S. J., Forde, C., Howell, A., Lalloo, F. I., & Woodward, E. R. (2024) · Genetics in Medicine · doi:10.1016/j.gim.2024.101172 · Cited by 7 · see citing works
Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study
Safra, T., Waissengrin, B., Gerber, D., Bernstein‐Molho, R., Klorin, G., Salman, L., Josephy, D., Chen‐Shtoyerman, R., Bruchim, I., Frey, M. K., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.06.009 · Cited by 7 · see citing works
Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study
Matsuo, K., Mandelbaum, R. S., Machida, H., Yoshihara, K., Matsuzaki, S., Klar, M., Muggia, F. M., Roman, L. D., & Wright, J. D. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05508-3 · Cited by 7 · see citing works
Uptake of Risk Reducing Mastectomy in Older BRCA1/2 and PALB2 Carriers Undergoing Genetic Testing after 60 Years of Age
Melanson, A., Mashal, S., Apostolova, C., Ferroum, A., Basik, M., Boileau, J. F., Martel, K., Meterissian, S. H., Wong, N., Weber, E., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18343-0 · Cited by 6 · see citing works
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2
Apostol, A. I., Gronwald, J., Cybulski, C., Kim, R. H., Møller, P., Karlan, B. Y., Bordeleau, L. J., Schrader, I., y Cajal, T. R., Pal, T., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01648 · Cited by 6 · see citing works
Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry
Walker, M. J., Mirea, L., Cooper, K. L., Nabavi, M., Glendon, G., Andrulis, I. L., Knight, J. A., O’Malley, F. P., & Chiarelli, A. M. (2013) · Familial Cancer · doi:10.1007/s10689-013-9689-9 · Cited by 6 · see citing works
Surgery and prophylactic surgery in hereditary breast cancer
Morrow, M. (2021) · The Breast · doi:10.1016/j.breast.2021.12.010 · Cited by 5 · see citing works
Stage IV Non-breast Cancer Patients and Screening Mammography: It is Time to Stop
Gentle, C. K., Alkhatib, H., Valente, S. A., Tu, C., & Pratt, D. A. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12132-9 · Cited by 4 · see citing works
PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer
Yuan, H., Xiu, L., Li, N., Li, Y., Wu, L., & Yao, H. (2024) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2024.35.e51 · Cited by 4 · see citing works
When to Consider Risk‐Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges
Speight, B., & Tischkowitz, M. D. (2017) · Journal of Genetic Counseling · doi:10.1007/s10897-017-0136-1 · Cited by 4 · see citing works
Electrochemical Determination of Label Free BRCA Hybridization by Single Use Antioxidant Modified Electrode
Muti, M., & Muti, M. (2017) · Electroanalysis · doi:10.1002/elan.201700256 · Cited by 3 · see citing works
Is There a Role for Risk-Reducing Bilateral Breast Surgery in BRCA1/2 Ovarian Cancer Survivors? An Observational Study
de Oliveira, D., Fernandes, S., Miguel, I. M. C., Fragoso, S., & Vaz, F. (2023) · Current Oncology · doi:10.3390/curroncol30090567 · Cited by 2 · see citing works
Breast cancer outcomes in women with ovarian cancer and a pathogenic germline BRCA mutation
Ain, Q., O’Connell, R. L., Swarnkar, P. K., McVeigh, T. P., George, A. J., Tasoulis, M. K., Gui, G. P. H., Wiggins, J. M., Khan, A., Krupa, K. D. C., et al. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.109380 · Cited by 2 · see citing works
Breast cancer incidence and subtype patterns among BRCA-mutated ovarian cancer patients: a systematic review and meta-analysis
Wagner, P. H. D. S., Matheus, G. T. F. U., Ribeiro, D. M., Magalhães, M. C. F., & de Moraes, F. C. A. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03320-x · Cited by 1 · see citing works
Bilateral synchronous breast cancer developed as metachronous malignancy after therapy of other primaries
Kurzyński, M., Mituś, J. W., Kołodziej-Rzepa, M., & Sas-Korczyńska, B. (2018) · Ginekologia Polska · doi:10.5603/gp.a2018.0041 · Cited by 1 · see citing works
Management of Hereditary Breast Cancer: An Overview
Kattepur, A. K., & Gopinath, K. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-4546-4_18 · Cited by 1 · see citing works
Risk Factors for Double Primary Breast and Ovarian Cancer in Women Across the Risk Spectrum
Ferris, J. S. (2018) · doi:10.7916/d89k5v4q
Hereditary Breast/Ovarian Cancer Syndrome: *BRCA2*
Hicks, D. G., & Lester, S. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37712-6.50107-1
Hereditary breast cancer and ovarian cancer: clinical course and treatment
Семиглазов, В. В., Протасова, А. Э., & Kalikeev, G. K. (2020) · Tumors of female reproductive system · doi:10.17650/1994-4098-2020-16-4-54-65
Breast Cancer Risk-reducing Strategies in BRCA1/2 Mutation Carriers
Heemskerk‐Gerritsen, B. A. M. (2014) · RePub (Erasmus University Rotterdam)
Self-citation
Characteristics of second primary breast cancer after ovarian cancer: a Korea central cancer registry retrospective study
Lee, E., Lim, J., Ha, H. I., Lim, M. C., Chang, Y. J., Won, Y.-J., & Jung, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1208320
Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report
Yuan, H., Zhang, R., Li, N., & Yao, H. (2024) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-024-00274-8
BRCA1/2 Carriers With Breast‐Ovarian Double Primary Cancers Versus Ovarian Cancer Alone: Mutation Profiles and Survival Outcomes
Wang, T., Li-dan, Z., Song, Y., Wu, Y., 樊翌明, Wu, M., Huang, C., Yan, L., Zhang, Y., 杨谢兰, et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70759

Abstract P2-07-04: Risk of primary and contralateral breast cancer in BRCA1/2 mutation carriers previously affected with ovarian cancer
Heemskerk‐Gerritsen, B. A. M., Hooning, M., van Doorn, H. C., Collee, M., Koppert, L. B., Jager, A., van den Ouweland, A., Netherlands, H., Seynaeve, C., & Kriege, M. (2017) · Cancer Research · doi:10.1158/1538-7445.sabcs16-p2-07-04
Self-citation
P4-11-04: Risk of Primary (PBC) and Contralateral Breast Cancer (CBC) after Ovarian Cancer (OC) in BRCA1 and BRCA2 Mutation Carriers; Implications for Surveillance and Risk Reducing Mastectomy.
Seynaeve, C., Vencken, P. M. L. H., Hooning, M., Menke-Pluymers, M., Heemskerk-Gerritsen, A., van, D. L., Collee, M. J., Jager, A., Van, M. K., Burger, C. W., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.sabcs11-p4-11-04
Self-citation
Contralateral Breast Cancer in BRCA1/2 Mutation Carriers: Risk Assessment by Age at Diagnosis of the First Primary Breast Cancer.
Hooning, M. J., Heemskerk‐Gerritsen, B. A. M., Jager, A., Collee, M. J., van den Ouweland, A., Menke-Pluymers, M., van Geel, B., van Doorn, L., Linthorst, M., Bartels, C. C. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-903 · Cited by 1 · see citing works
Self-citation
Risk of metachronous breast cancer after BRCA mutation–associated ovarian cancer
Domchek, S. M., Jhaveri, K. L., Patil, S. N., Stopfer, J. E., Hudis, C. A., Powers, J. M., Stadler, Z. K., Goldstein, L., Kauff, N. D., Khasraw, M., et al. (2012) · Cancer · doi:10.1002/cncr.27842 · Cited by 60 · see citing works
The Risk of Ovarian Cancer After Breast Cancer in BRCA1 and BRCA2 Carriers
Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Foulkes, W. D., Warner, E., Olopade, O. I., Eisen, A. F., Wever, B., et al. (2005) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000157167.69728.df · Cited by 16 · see citing works

Authors: Vencken, P. M. L. H., Kriege, M., Hooning, M., Menke‐Pluymers, M. B., Heemskerk‐Gerritsen, B. A. M., van Doorn, L. C., Collée, M. M., Jager, A., van Montfort, C., Burger, C. W., & Seynaeve, C.
Affiliations: Erasmus MC (NL)
ORCID: Hooning, Maartje
Heemskerk‐Gerritsen, Bernadette A. M.
Jager, Agnes
Burger, Curt W.
Venue: Cancer
Publisher: Wiley
Published: 2012-11-16
Volume: 119
Issue: 5
Pages: 955-962
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.27839
OpenAlex: W1540810425
Cited by: 40
References: 43
Citations by year: 2026: 2 · 2025: 2 · 2024: 5 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 5 · 2016: 3 · 2015: 2 · 2014: 4 · 2013: 1
FWCI: 1.34
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords: BRCA1 mutation carriers, BRCA2 mutation carriers, epithelial ovarian cancer, primary breast cancer, contralateral breast cancer, cancer risk, competing risks, cancer mortality, hereditary cancer predisposition, genetic counseling
MeSH terms: Adolescent, Adult, Aged, Breast Neoplasms, Child, Child, Preschool, Female, Genetic Counseling, Heterozygote, Humans, Infant, Middle Aged, Mutation, Neoplasms, Multiple Primary, Ovarian Neoplasms, Risk, Genes, BRCA1, Genes, BRCA2, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks